Novo Nordisk A/S
Copenhagen : NOVO B

June 07, 2012 20:02 ET

Novo Nordisk A/S: FDA extends regulatory review period for insulin degludec and insulin degludec/insulin aspart by three months

BAGSVAERD, DENMARK--(Marketwire - Jun 7, 2012) -

Company Announcement No 37 / 2012:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE


Contact Information